PDCD1 and non-small cell lung carcinoma: Studies have shown that some NSCLC patients without PD-L1 expression may respond to anti-PD-1 drugs (24), and 50% of patients with high PD-L1 expression in tumors cannot benefit from first-line pembrolizumab (anti-PD-1 antibody) (9).